Granules India Receives US FDA Approval For Generic Micro-K ER Capsules

Granules India Limited announced that the US Food & Drug Administration (FDA) has approved its Abbreviated New Drug Application (ANDA) for potassium chloride extended-release capsules USP, 8 mEq (600 mg) and 10 mEq (750 mg).It is bioequivalent to the reference listed drug product (RLD), Micro-K extended-release capsules, 8 mEq and 10 mEq, of Nesher Pharmaceuticals (USA) LLC. The product would be manufactured at our Hyderabad facility and is expected to be launched shortly."We are pleased to announce approval of potassium chloride capsule product within first review cycle of 10 months from filing date. This is fourth ANDA approval in our potassium chloride product basket." said Priyanka Chigurupati, executive director, Granules Pharmaceuticals, Inc., commenting on the approval.Potassium chloride is indicated for the treatment of patients with hypokalemia with or without metabolic alkalosis, in digitalis intoxications, and in patients with hypokalemic familial periodic paralysis. It is also indicated for the prevention of hypokalemia in patients who would be at particular risk if hypokalemia were to develop e.g., digitalized patients or patients with significant cardiac arrhythmias, hepatic cirrhosis with ascites, states of aldosterone excess with normal renal function, potassium-losing nephropathy, and certain diarrheal states.Granules has a total of 37 ANDA approvals from US FDA (36 final approvals and 1 tentative approvals).Potassium chloride ER capsule products had US sales of approximately $43 million for the most recent twelve months ending in December 2020 according to IQVIA Health.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!